Biotech Kardigan Jumps 1.9% After $400 Million IPO in Trading Debut
Biotech Kardigan gained nearly 2% in its stock market debut after completing a $400 million initial public offering that priced at the…
Biotech Kardigan gained nearly 2% in its stock market debut after completing a $400 million initial public offering that priced at the…
Kardigan's upsized $400 million IPO for heart disease therapies highlights growing investor confidence in biotech innovation and sets a favorable precedent for…
Heart health biotech Kardigan files for a $373.3 million U.S. IPO, signaling growing investor interest in cardiovascular therapies and testing the IPO…
Kardigan IPO filing marks a milestone in cardiovascular drug development, highlighting renewed investor interest in biotech innovations beyond oncology.